|  | Cancer | Lung Cancer

Lung Nodules: Evaluation, Risk Stratification, and Follow-Up

A lung nodule (pulmonary nodule) is a focal opacity ≤3 cm surrounded by lung parenchyma. >3 cm is a mass. Nodules are common incidental findings on CT (up to 50% of adults).

Morphologic Classification

  • Solid: Uniform soft-tissue attenuation; obliterates vessels.
  • Part-solid: Solid + ground-glass components; higher malignancy risk.
  • Ground-glass (GGN): Hazy opacity preserving vessels; pure GGN vs. part-solid.

Risk Stratification (Fleischner Society 2017 Guidelines — Simplified)

Clinical Assessment

  1. Compare with prior imaging (stability >2 yrs = benign).
  2. Calculate probability: Brock model, Mayo Clinic model, VA model.
  3. PET-CT: Sensitivity ~90% for >8 mm solid; false negatives in carcinoid, AIS, MIA; false positives in infection/inflammation.
  4. Biopsy: CT-guided (peripheral), bronchoscopic (central), surgical (diagnostic + therapeutic).

Benign Etiologies

  • Granulomas (TB, histoplasmosis), hamartomas, intrapulmonary lymph nodes, organizing pneumonia, rheumatoid nodules, arteriovenous malformations.

Multidisciplinary discussion (pulmonology, radiology, thoracic surgery) recommended for indeterminate nodules >8 mm or growing.

Lung Cancer - Related Articles

Health Sciences © https://www.222health.com

Nodule TypeSizeLow Risk (No Hx)High Risk (Smoking, FHx, etc.)
Solid<6 mmNo routine follow-upOptional CT at 12 mo
Solid6–8 mmCT at 6–12 mo, then 18–24 moCT at 6–12 mo, then 18–24 mo
Solid>8 mmCT at 3 mo, PET/CT, or biopsyCT at 3 mo, PET/CT, or biopsy
Part-solid<6 mmNo routine follow-upCT at 12 mo
Part-solid≥6 mmCT at 3–6 mo; if persistent, PET/biopsyCT at 3–6 mo; if persistent, PET/biopsy
Pure GGN<6 mmNo routine follow-upCT at 12 mo
Pure GGN≥6 mmCT at 6–12 mo, then q2y ×5 yrsCT at 6–12 mo, then q2y ×5 yrs